GRACEcast Radiation Oncology Audio

By cancerGRACE - H. Jack West, MDMedicine Education

GRACEcast Radiation Oncology Audio episodes

July 08, 2014 What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
4 min
July 06, 2014 Treating Newly Diagnosed Kidney Cancer
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.
4 min
July 03, 2014 MET-Amplified Lung Cancer: A New Target for XALKORI?
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
8 min
July 01, 2014 The Hottest Thing in Late Stage Kidney Cancer
Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.
3 min
June 29, 2014 CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer
Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.
5 min
June 26, 2014 The Promise of PD1 Inhibitors in Kidney Cancer
Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.
4 min
June 25, 2014 FGFR and Its Role in Treating Squamous Cell Lung Cancer
Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.
3 min
June 24, 2014 AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer
EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.
12 min
June 23, 2014 What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?
"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.
3 min
June 22, 2014 What Is Non-Clear Cell Kidney Cancer?
Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.
5 min

About GRACEcast Radiation Oncology Audio

From the publisher's feed

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to…